Moreover, the accumulation of Dylight-755-labeled Z239-1907 at the tumor site was achieved as early as 30 min and disappeared within 24 h post-injection, similar to published studies such as affibody-based nanoprobes specifically targeting HER-2 and affibody and affitoxin that target EBV-LMP2 [40,62]. The gene discussed is PSMB9; the disease is neoplasm.